The news that President Trump’s administration has told scientists employed by the National Institutes of Health (NIH) that they can’t buy any new human fetal tissue for research has left many scientists frustrated and worried. The news has also highlighted the reason why voters created CIRM in the first place and the importance of having … Continue reading NIH-scientists are told to stop buying fetal tissue for research, highlighting importance of CIRM’s voter-created independence
National Institutes of Health
California’s Stem Cell Agency Accelerates Treatments to Patients
The following article is an Op Ed that appeared in today's print version of the San Francisco Chronicle Biotechnology was born in California in the 1970s based on the discovery out of one of its universities and California is responsible for an industry that has impacted the lives of billions of people worldwide. In 2004, … Continue reading California’s Stem Cell Agency Accelerates Treatments to Patients
Has Regenerative Medicine Come of Age?
For the past few years the Signals blog site - which offers an insiders’ perspectives on the world of regenerative medicine and stem cell research - has hosted what it calls a "Blog Carnival". This is an event where bloggers from across the stem cell field are invited to submit a piece based on a … Continue reading Has Regenerative Medicine Come of Age?
Overcoming one of the biggest challenges in stem cell research
Imagine you have just designed and built a new car. Everyone loves it. It’s sleek, fast, elegant, has plenty of cup holders. People want to buy it. The only problem is you haven’t built an assembly line to make enough of them to meet demand. Frustrating eh. Overcoming problems in manufacturing is not an issue … Continue reading Overcoming one of the biggest challenges in stem cell research
Turning the corner with the FDA and NIH; CIRM creates new collaborations to advance stem cell research
This blog is part of the Month of CIRM series on the Stem Cellar A lot can change in a couple of years. Just take our relationship with the US Food and Drug Administration (FDA). When we were putting together our Strategic Plan in 2015 we did a survey of key players and stakeholders at … Continue reading Turning the corner with the FDA and NIH; CIRM creates new collaborations to advance stem cell research
From trauma to treatment: a Patient Advocate’s journey from helping her son battle a deadly disease to helping others do the same
For every clinical trial CIRM funds we create a Clinical Advisory Panel or CAP. The purpose of the CAP is to make recommendations and provide guidance and advice to both CIRM and the Project Team running the trial. It’s part of our commitment to doing everything we can to help make the trial a success … Continue reading From trauma to treatment: a Patient Advocate’s journey from helping her son battle a deadly disease to helping others do the same
CIRM & NIH: a dynamic duo to advance stem cell therapies
There’s nothing more flattering than to get an invitation, out of the blue, from someone you respect, and be told that they are interested in learning about the way you work, to see if it can help them improve the way they work. That’s what happened to CIRM recently. I will let Randy Mills, who … Continue reading CIRM & NIH: a dynamic duo to advance stem cell therapies
The Stem Cellar 